Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: Results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)

Circulation

Volumn 112, Issue 22, 2005, Pages 3391-3399

  White, Harvey D ^a   Aylward, Philip E G ^b   Huang, Zhen ^c   Dalby, Anthony J ^d   Weaver, W Douglas ^e   Barvik, Ståle ^f   Marin Neto, José Antonio ^g   Murin, Jan ^h   Nordlander, Rolf O ⁱ   Van Gilst, Wiek H ^j   Zannad, Faiez ^k   McMurray, John J V ^l   Califf, Robert M ^c   Pfeffer, Marc A ^m  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d MILPARK HOSPITAL   (South Africa)

^e HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^f STAVANGER UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j UNIVERSITY OF GRONINGEN   (Netherlands)

^k Ctr Hospitalier Univ de Nancy   (France)

^l WESTERN INFIRMARY   (United Kingdom)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

Aging; Angiotensin converting enzyme inhibitors; Captopril; Myocardial infarction; Valsartan

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; STATINE DERIVATIVE; VALSARTAN; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ACUTE HEART INFARCTION; ADULT; AGE; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; FEMALE; HEART ARREST; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART REINFARCTION; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESUSCITATION; SIDE EFFECT; STROKE; TASTE DISORDER; TREATMENT OUTCOME; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONGESTIVE HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; SYSTOLE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CAPTOPRIL; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; MORBIDITY; MORTALITY; MYOCARDIAL INFARCTION; SYSTOLE; TETRAZOLES; TREATMENT OUTCOME; VALINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33644876849     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.105.551143     Document Type: Article

References (30)

1. Petrie MC, Berry C, Stewart S, McMurray JJ. Failing ageing hearts. Eur Heart J. 2001;22:1978-1990.
2. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-1456; erratum 1995;274:462.
3. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E, for the ACE-Inhibitor Myocardial Infarction Collaborative Group. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet. 2000;355:1575-1581.
4. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
5. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
6. Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002;360:752-760.
7. McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767-771.
8. Pfeffer MA, McMurray J, Leizorovicz A, Maggioni AP, Rouleau JL, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers MA, Velazquez E, Califf R. Valsartan in Acute Myocardial Infarction Trial (VALIANT): rationale and design. Am Heart J. 2000;140:727-750.
9. Jonckheere AR. A distribution-free k-sample test against ordered alternatives. Biometrika. 1954;41:133-145.
10. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
11. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
12. O'Keefe S, Harvey G, Lye M. Use of angiotensin-converting enzyme inhibitors in elderly patients with heart failure. Age Ageing. 1998;27:297-301.
13. Krumholz HM, Wang Y, Parent EM, Mockalis J, Petrillo M, Radford MJ. Quality of care for elderly patients hospitalized with heart failure. Arch Intern Med. 1997;157:2242-2247.
14. Wolinsky FD, Overhage JM, Stump TE, Lubitz RM, Smith DM. The risk of hospitalization for congestive heart failure among older adults. Med Care. 1997;10:1031-1043.
15. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, Flaker GC, Braunwald E, Pfeffer MA. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol. 2003;42:1446-1453.
16. Fraticelli A, Gesuita R, Vespa A, Paciaroni E. Congestive heart failure in the elderly requiring hospital admission. Arch Gerontol Geriatr. 1996;23:225-238.
17. Cocchi A, Zuccala G, Menichelli P, Antonelli Incalzi R, Del Sindaco D, Alimenti M, Carbonin PU. Congestive heart failure in the elderly: an intriguing clinical reality. Cardiol Elderly. 1994;2:227-232.
18. Heerdink ER, Leufkens HG, Herings RMC, Ottervanger JP, Bruno HC, Bakker A. NSAIDS associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158:1108-1112.
19. Lakatta EG. Changes in cardiovascular function with aging. Eur Heart J. 1990;11(suppl C):22-29.
20. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362:777-781.
21. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PWI, Young JB, Probstfield J. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). Am Heart J. 1996;131:350-355.
22. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] trial). Am J Cardiol. 1992;70:479-487.
23. Mets T, De Bock V, Praet JP, First-dose hypotension, ACE inhibitors, and heart failure in the elderly. Lancet. 1992;339:1487. Letter.
24. Sioufi A, Marfil F, Jaouen A, Cardot JM, Godbillon J, Ezzet F, Lloyd P. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos. 1998;19:237-244.
25. Grossman E, Messerli FH, Neutel JM. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors. Arch Intern Med. 2000;160:1905-1907.
26. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
27. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-1390.
28. Rathore SS, Mehta RH, Wang Y, Radford MJ, Krumholz HM. Effects of age on the quality of care provided to older patients with acute myocardial infarction. Am J Med. 2003;114:307-315.
29. The effect of diltiazem on mortality and reinfarction after myocardial infarction: the Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med. 1988;319:385-392.
30. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705-708.